Idefirix

Imlifidase, the active ingredient in Idefirix, is a IgG‑degrading enzyme (recombinant protease) presented as a solution for injection for intravenous use. It is employed to rapidly cleave circulating IgG antibodies, reducing donor‑specific antibodies and facilitating desensitization in HLA‑incompatible kidney transplantation.

GNH USA supplies Idefirix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Idefirix acts as a targeted immunosuppressant for patients undergoing antibody‑mediated transplant preparation. - HLA‑incompatible kidney transplantation: Enables desensitization by rapidly degrading circulating IgG antibodies, lowering donor‑specific antibody levels and reducing risk of antibody‑mediated rejection. - Pre‑transplant desensitization: Provides a rapid reduction of sensitizing antibodies, allowing otherwise incompatible donors to become viable. - Highly sensitized renal transplant candidates: Improves eligibility for transplantation by decreasing panel‑reactive antibody burden.

Idefirix may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion‑related reactions: mild fever, chills, or flushing. - Headache: transient and usually self‑limiting. - Nausea or mild gastrointestinal discomfort. - Fatigue or generalized weakness. - Transient hypotension during infusion.

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction. - Cytokine release syndrome with high fever and hypotension. - Severe infections due to profound immunosuppression. - Thromboembolic events such as deep vein thrombosis. - Acute renal impairment. - Immune complex–mediated vasculitis.

Prior to initiating Idefirix therapy, several safety considerations should be observed. - Assess donor‑specific antibody levels: confirm the need for desensitization. - Monitor vital signs and infusion reactions continuously during administration. - Avoid use in patients with known hypersensitivity to recombinant proteases. - Evaluate infection risk: defer treatment in active uncontrolled infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idefirix can interact with other agents that modify immune function or hemostasis.

Major Interactions (Avoid): - Concurrent potent immunosuppressants: may markedly increase infection risk. - Live vaccines: risk of uncontrolled infection due to immunosuppression. - Plasma exchange therapy performed shortly after infusion: may reduce drug efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, heparin): monitor for bleeding complications. - Systemic corticosteroids: may augment overall immunosuppressive effect. - Cytokine‑targeting agents (e.g., tocilizumab): may alter immune response dynamics.